BACE1 and Alzheimer disease: Cheng et al. reported increased serum level and activity of beta-secretase (BACE1) in patients with mild cognitive impairment (MCI) and AD that are well correlated with clinical severity, thus likely applicable to the prediction of AD at early stages (Cheng et al., 2014).